Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice

Cancer Investigation

Volumn 28, Issue 1, 2010, Pages 74-84

  Jiang, Hongchi ^a   Tao, Weiyang ^a   Zhang, Mu ^a   Pan, Shangha ^a   Kanwar, Jagat R ^c   Sun, Xueying ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Angiogenesis; Breast cancer; Low dose metronomic chemotherapy; Lymphangiogenesis; Maximum tolerable dose; Metastasis; Paclitaxel; Thrombospondin 1; Vascular endothelial growth factor

Indexed keywords

PACLITAXEL; THROMBOSPONDIN 1; VASCULOTROPIN C;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LIVER METASTASIS; LIVER TOXICITY; LOW DOSE METRONOMIC CHEMOTHERAPY; LOW DRUG DOSE; LUNG METASTASIS; LYMPHANGIOGENESIS; MAXIMUM TOLERATED DOSE; METASTASIS INHIBITION; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR VASCULARIZATION; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; FEMALE; LYMPHANGIOGENESIS; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; THROMBOSPONDIN 1; TIME FACTORS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 72449150594     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900902744510     Document Type: Article

References (43)

1. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55, 74-108.
2. Demichell, R.; Valagussa, P.; Bonadonna, G. Does surgery modify growth kinetics of breast cancer micrometastases. Br J Cancer 2001, 85, 490-492.
3. Hansen, E.; Wolff, N.; Knuechel, R.; Ruschoff, J.; Hofstaedter, F.; Taeger, K. Tumour cells in bloodshed from the surgical field. Arch Surg 1995, 130, 387-393.
4. Clemons, M.; Goss, P. Estrogen and the risk of breast cancer. N Engl J Med 2001, 344, 276-285.
5. Miller, W.R. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. Semin Oncol 2003, 30, 3-11.
6. Arbuck, S.G.; Dorr, A.; Friedman, M.A. Paclitaxel (Taxol) in breast cancer. Hematol Oncol Clin North Am 1994, 8, 121-140.
7. Horwitz, S.B.; Cohen, D.; Rao, S.; Ringel, I.; Shen, H.J.; Yang, C.P. Paclitaxel: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993, 15, 55-61.
8. Weisis, R.B.; Donehower, R.C.; Wiernik, P.H.; Ohnuma, T.; Gralla, R.J.; Trump, D.L.; et al. Hypersensitivity reactions from paclitaxel. J Clinl Oncol 1990, 8, 1263-1268.
9. Lennern̈as, B.; Albertsson, P.; Damber, J.E.; Norrby, K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. APMIS 2004, 112, 201-209.
10. Bocci, G.; Nicolaou, K.C.; Kerbel, R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002, 62, 6938-6943.
11. Ng, S.S.; Sparreboom, A.; Shaked, Y.; Lee, C.; Man, S.; Desai, N.; et al. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res 2006, 12, 4331-433812.
12. Drevs, J.; Fakler, J.; Eisele, S.; Medinger, M.; Bing, G.; Esser, N.; et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004, 24, 1759-1763.
13. Klement, G.; Huang, P.; Mayer, B.; Green, S.K.; Man, S.; Bohlen, P.; et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrugresistant human breast cancer xenografts. Clin Cancer Res 2002, 8, 221-232.
14. Radice, D.; Redaelli, A. Breast cancer management: quality-of-life and cost considerations. Pharmacoeconomics 2003, 21, 383-396. (Pubitemid 36461402)
15. Pulaski, B.A.; Ostrand-Rosenberg, S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998, 58, 1486-1493.
16. Aslakson, C.J.; Miller, F.R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992, 52, 1399-1405.
17. Kanwar, J.R.; Palmano, K.P.; Sun, X.; Haggarty, N.; Kanwar, R.K.; Gupta, R.; et al. "Iron-saturated" lactoferrin exhibits significantly greater anti-tumour activity than natural lactoferrin in combination with cancer chemotherapy. Cancer Immunol Immunother 2008, 86, 277-288.
18. Kuwabara, T.; Cogan, D.G. Studies of retinal vascular patterns: Part I normal architecture. Arch Ophthalmol 1960, 64, 904-911.
19. Sun, X.; Qiao, H.; Jiang, H.; Zhi, X.; Liu, F.; Wang, J.; et al. Intramuscular delivery of anti-angiogenic genes suppresses secondary metastases after removal of primary tumors. Cancer Gene Ther 2005, 12, 35-45.
20. Ma, L.; Luo, L.; Qiao, H.; Dong, X.; Pan, S.; Jiang, H.; et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol 2006, 46, 98-106.
21. Liu, F.; Wang, P.; Jiang, X.; Tan, G.; Qiao, H.; Jiang, H.; et al. Antisense hypoxia-inducible factor 1 á gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinomas. Cancer Sci 2008, 99, 2055-2061.
22. Melichar, B.; Dvorak, J.; Hyspler, R.; Zadak, Z. Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy 2005, 51, 336-338.
23. Cunnick, G.H.; Jiang, W.G.; Gomez, K.F.; Mansel, R.E. Lymphangiogenesis and breast cancer metastasis. Histol Histopathol 2002, 17, 863-870.
24. Takahashi, Y.; Mai, M.; Sawabu, N.; Nishioka, K. A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer. Pancreas 2005, 30, 206-210.
25. Bocci, G.; Francia, G.; Man, S.; Lawler, J.; Kerbel, R.S. Thrombospondin 1, amediator of the antiangiogenic effects of low-dose metronomicchemotherapy. Proc Natl Acad Sci USA 2003, 100, 12917-12922.
26. Bell, K.A.; Perna, A.G.; Hsu, S. Mucositis as a treatmentlimiting side effect in the use of capecitabine for the treatment of metastatic breast cancer. J Am Acad Dermatol 2001, 45, 790.
27. Ogawa, Y.; Ishikawa, T.; Chung, S.H.; Ikeda, K.; Takashima, T.; Onoda, N.; et al. Oral UFT and cyclophosphamide combination chemotherapy for metastatic breast cancer. Anticancer Res 2003, 23, 3453-3457.
28. Wang, J.; Lou, P.; Lesniewski, R.; Henkin, J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003, 14, 13-19.
29. Bertolini, F.; Paul, S.; Mancuso, P.; Monestiroli, S.; Gobbi, A.; Shaked, Y.; et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003, 63, 4342-4346.
30. Kabrun, N.; Buhring, H.J.; Choi, K.; Ullrich, A.; Risau, W.; Keller, G. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 1997, 124, 2039-2048.
31. Shibuya, M.; Claesson-Welsh, L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 12, 549-560.
32. Joukov, V.; Pajusola, K.; Kaipainen, A.; Chilov, D.; Lahtinen, I.; Kukk, E.; et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996, 15, 290-298.
33. Dawson, D.W.; Pearce, S.F.; Zhong, R.; Silverstein, R.L.; Frazier, W.A.; Bouck, N.P. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997, 138, 707-717.
34. Damber, J.E.; Vallbo, C.; Albertsson, P.; Lennernas, B.; Norrby, K. The antitumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 2006, 58, 354-360.
35. Hamano, Y.; Sugimoto, H.; Soubasakos, M.A.; Kieran, M.; Olsen, B.R.; Lawler, J.; et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004, 64, 1570-1574.
36. Munoz, R.; Shaked, Y.; Bertolini, F.; Emmenegger, U.; Man, S.; Kerbel, R.S. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005, 14, 466-479.
37. Widakowich, C.; Dinh, P.; de Azambuja, E.; Awada, A.; Piccart- Gebhart, M. HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? Anticancer Agents Med Chem 2008, 8, 488-496.
38. Izumi, Y.; Xu, L.; di Tomaso, E.; Fukumura, D.; Jain, R.K. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416, 279-280.
39. Orlando, L.; Cardillo, A.; Ghisini, R.; Rocca, A.; Balduzzi, A.; Torrisi, R.; et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006, 6, 225-232.
40. Dellapasqua, S.; Bertolini, F.; Bagnardi, V.; Campagnoli, E.; Scarano, E.; et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26, 4899-4905.
41. Peltier, S.; Oger, J.M.; Lagarce, F.; Couet, W.; Benôit, J.P. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res 2006, 23, 1243-1250
42. Br̈oker, L.E.; Valdivieso, M.; Pilat, M.J.; Deluca, P.; Zhou, X.; Parker, S.; et al. Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. Clin Cancer Res 2008, 14, 4186-4191.
43. Chu, Z.; Chen, J.S.; Liau, C.T.; Wang, H.M.; Lin, Y.C.; Yang, M.H.; et al. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anticancer Drugs 2008, 19, 275-281.